EL-07
Written by the Elevate Clinical Team
Cognitive concerns warrant review of sleep, medications, mood and other potential contributors. The preparation and route should follow a clinical assessment, not a general performance claim.
3 therapies
EL-07 · Cognitive
Nasal
$349 / month
750 mcg · 6 mL
PCAC's July 2026 recommendation is advisory, not final; this substance remains off the 503A list. HHS/FDA announced an interim enforcement discretion policy on October 28, subject to the conditions set out in that policy. It is not FDA approval and does not apply to research-use-only products. We are confirming pharmacy compliance before changing what we dispense. Current FDA / PCAC status.
EL-07 · Cognitive
Nasal
$399 / month
750 mcg per 0.1 mL spray
PCAC's July 2026 recommendation is advisory, not final; this substance remains off the 503A list. HHS/FDA announced an interim enforcement discretion policy on October 28, subject to the conditions set out in that policy. It is not FDA approval and does not apply to research-use-only products. We are confirming pharmacy compliance before changing what we dispense. Current FDA / PCAC status.
EL-07 · Cognitive
Injection
$429 / month
1,000 mcg/mL · 5 mL vial
PCAC's July 2026 recommendation is advisory, not final; this substance remains off the 503A list. HHS/FDA announced an interim enforcement discretion policy on October 28, subject to the conditions set out in that policy. It is not FDA approval and does not apply to research-use-only products. We are confirming pharmacy compliance before changing what we dispense. Current FDA / PCAC status.
Nasal and injectable formulations are distinct prescribing choices. Emerging evidence must be weighed against uncertainty, medical history and monitoring requirements.
A treatment plan also includes instructions, monitoring and a review of changes in health or medications. Questions about suitability or administration belong with the clinical team.
Written by the Elevate Clinical Team